Sushrusha Nayak, Ph.D. - Publications

2010 University of Florida, Gainesville, Gainesville, FL, United States 

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Doerfler PA, Nayak S, Corti M, Morel L, Herzog RW, Byrne BJ. Targeted approaches to induce immune tolerance for Pompe disease therapy. Molecular Therapy. Methods & Clinical Development. 3: 15053. PMID 26858964 DOI: 10.1038/mtm.2015.53  0.44
2016 Doerfler PA, Todd AG, Clément N, Falk DJ, Nayak S, Herzog RW, Byrne BJ. Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease. Human Gene Therapy. 27: 43-59. PMID 26603344 DOI: 10.1089/hum.2015.103  0.44
2015 Doerfler PA, Nayak S, Herzog RW, Morel L, Byrne BJ. BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease. Clinical Immunology (Orlando, Fla.). 158: 140-7. PMID 25842186 DOI: 10.1016/j.clim.2015.03.022  0.44
2015 Biswas M, Sarkar D, Kumar SR, Nayak S, Rogers GL, Markusic DM, Liao G, Terhorst C, Herzog RW. Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood. 125: 2937-47. PMID 25833958 DOI: 10.1182/blood-2014-09-599266  0.44
2014 Corti M, Elder M, Falk D, Lawson L, Smith B, Nayak S, Conlon T, Clément N, Erger K, Lavassani E, Green M, Doerfler P, Herzog R, Byrne B. B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Molecular Therapy. Methods & Clinical Development. 1. PMID 25541616 DOI: 10.1038/mtm.2014.33  0.44
2014 Nayak S, Doerfler PA, Porvasnik SL, Cloutier DD, Khanna R, Valenzano KJ, Herzog RW, Byrne BJ. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. Plos One. 9: e98336. PMID 24897114 DOI: 10.1371/journal.pone.0098336  0.44
2014 Elmallah MK, Falk DJ, Nayak S, Federico RA, Sandhu MS, Poirier A, Byrne BJ, Fuller DD. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 702-12. PMID 24336173 DOI: 10.1038/mt.2013.282  0.44
2013 Markusic DM, Hoffman BE, Perrin GQ, Nayak S, Wang X, LoDuca PA, High KA, Herzog RW. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. Embo Molecular Medicine. 5: 1698-709. PMID 24106230 DOI: 10.1002/emmm.201302859  0.44
2013 Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, Herzog RW, Modica RF, Lew J, Lawrence RM, Byrne BJ. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. The Journal of Pediatrics. 163: 847-54.e1. PMID 23601496 DOI: 10.1016/j.jpeds.2013.03.002  0.44
2012 Nayak S, Sivakumar R, Cao O, Daniell H, Byrne BJ, Herzog RW. Mapping the T helper cell response to acid α-glucosidase in Pompe mice. Molecular Genetics and Metabolism. 106: 189-95. PMID 22494547 DOI: 10.1016/j.ymgme.2012.03.009  0.44
2012 Kamarajugadda S, Stemboroski L, Cai Q, Simpson NE, Nayak S, Tan M, Lu J. Glucose oxidation modulates anoikis and tumor metastasis Molecular and Cellular Biology. 32: 1893-1907. PMID 22431524 DOI: 10.1128/MCB.06248-11  0.44
2011 Nayak S, Sarkar D, Perrin GQ, Moghimi B, Hoffman BE, Zhou S, Byrne BJ, Herzog RW. Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B. Frontiers in Microbiology. 2: 244. PMID 22279442 DOI: 10.3389/fmicb.2011.00244  0.44
2011 Moghimi B, Sack BK, Nayak S, Markusic DM, Mah CS, Herzog RW. Induction of tolerance to factor VIII by transient co-administration with rapamycin. Journal of Thrombosis and Haemostasis : Jth. 9: 1524-33. PMID 21585650 DOI: 10.1111/j.1538-7836.2011.04351.x  0.44
2011 Byrne BJ, Falk DJ, Pacak CA, Nayak S, Herzog RW, Elder ME, Collins SW, Conlon TJ, Clement N, Cleaver BD, Cloutier DA, Porvasnik SL, Islam S, Elmallah MK, Martin A, et al. Pompe disease gene therapy. Human Molecular Genetics. 20: R61-8. PMID 21518733 DOI: 10.1093/hmg/ddr174  0.44
2010 Liao G, Nayak S, Regueiro JR, Berger SB, Detre C, Romero X, de Waal Malefyt R, Chatila TA, Herzog RW, Terhorst C. GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells. International Immunology. 22: 259-70. PMID 20139172 DOI: 10.1093/intimm/dxq001  0.44
2010 Nayak S, Herzog RW. Progress and prospects: Immune responses to viral vectors Gene Therapy. 17: 295-304. PMID 19907498 DOI: 10.1038/gt.2009.148  0.44
2009 Martino AT, Nayak S, Hoffman BE, Cooper M, Liao G, Markusic DM, Byrne BJ, Terhorst C, Herzog RW. Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. Plos One. 4: e6376. PMID 19652717 DOI: 10.1371/journal.pone.0006376  0.44
2009 Cao O, Hoffman BE, Moghimi B, Nayak S, Cooper M, Zhou S, Ertl HC, High KA, Herzog RW. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1733-42. PMID 19603001 DOI: 10.1038/mt.2009.159  0.44
2009 Nayak S, Cao O, Hoffman BE, Cooper M, Zhou S, Atkinson MA, Herzog RW. Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells Journal of Thrombosis and Haemostasis. 7: 1523-1532. PMID 19583824 DOI: 10.1111/j.1538-7836.2009.03548.x  0.44
2009 Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Human Gene Therapy. 20: 767-76. PMID 19309290 DOI: 10.1089/hum.2008.161  0.44
2007 Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, Herzog RW. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood. 110: 1132-40. PMID 17438084 DOI: 10.1182/blood-2007-02-073304  0.44
Show low-probability matches.